Dual Therapy for Myopia Control - Summary - MDSpire

Dual Therapy for Myopia Control

Randomized trial shows combining atropine with DIMS lenses significantly reduces axial elongation in children

  • June 4, 2026

  • 4 min

Share

Objective:

To evaluate the effectiveness of combining low-dose atropine with Defocus Incorporated Multiple Segments (DIMS) spectacle lenses for myopia control in children.

Key Findings:
  • Axial elongation at 12 months was 0.18 mm in the atropine-only group compared to 0.07 mm in the combination group, a statistically significant difference of 0.11 mm.
  • Nearly 40% of children receiving combination therapy showed no axial elongation, compared to 12% in the control group.
  • Changes in spherical equivalent refraction (SER) were directionally favorable but not statistically significant.
Interpretation:

Limitations:
  • The study represents an interim analysis of a 24-month trial, with longer-term data needed to confirm durability of effect.
  • Questions remain regarding optimal atropine dosing and comparison with other strategies.
Conclusion:

Original Source(s)

Dual Therapy for Myopia Control

  • June 4, 2026

Related Content

Vitamin D May Reflect Myopia Risk

Narrative review linked lower vitamin D levels to greater myopia risk and higher omega-3 intake to lower risk, though outdoor exposure may explain the vitamin D association.

Advanced bilateral glaucoma decades after first-generation Fyodorov ‘collar-button’ anterior–posterior phakic intraocular lens implantation: a case report and clinical management considerations

Inside Focus A-Eye’s Inaugural Meeting

Sharon Bakalash, MD, PhD, CBA, describes how the interdisciplinary pre-ARVO forum explored ways to move AI from concept to clinic.